Track Grifols, S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Grifols, S.A. GRFS · Stock Open Grifols, S.A. in new tab

8.69 USD
P/E
10.60
EPS
0.82
Yield
0.73%
Safety Score
77
P/B
1.82
ROE
7.33
Beta
1.13
Target Price
10.37 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
P/E10.60
EPS0.82
Book Value4.78
Price to Book1.82
Debt/Equity112.10
% Insiders0.923%
Growth
Revenue Growth0.09%
Earnings Growth0.28%
Estimates
Forward P/E6.98
Forward EPS1.24
Target Mean Price10.37
Dividend
Dividend Yield0.73%
Annual dividends0.08 USD
Ex-Div. DateDec. 3, 2026
Payout28.31%
5y avg Yield2.40%

DCF valuation

Model fair value for Grifols, S.A. (GRFS)
Result
Sign in to run the valuation for GRFS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Buy · mean target 10.37 USD (low 9.00, high 11.73) · as of 16 Nov 2026
Low 9.00
Mean 10.37
High 11.73
Price 8.69
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Grifols, S.A. Logo Grifols, S.A. Analysis (GRFS)

Spain Health Care Official Website Stock

Is Grifols, S.A. a good investment? Grifols, S.A. (GRFS) is currently trading at 8.69 USD. Market analysts have a consensus price target of 10.37 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 10.60. This relatively low multiple may signal that Grifols, S.A. is undervalued compared to historical market norms.

Earnings Schedule: Grifols, S.A. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is 1.24.

For income investors, Grifols, S.A. pays a dividend yield of 0.73%. With a payout ratio of 28%, the dividend appears sustainable.

Investor FAQ

Does Grifols, S.A. pay a dividend?

Yes, it pays an annual dividend of 0.08 USD (0.73% yield).

What asset class is Grifols, S.A.?

Grifols, S.A. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of 0.82.

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Exchange Ticker
FRA (Germany) G0FB.F
NMS (United States) GRFS
Trades
Dividend Yield
0.73%
5y avg 2.40%
Annual Dividends
0.08USD
Next Ex. Div Date
Dec. 3, 2026
Payout Ratio
28.31%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.09 USD
July 9, 2027 (estimated) 0.0945
▸2026
0.23 USD
Dec. 11, 2026 0.1366
July 9, 2026 0.0945
▸2025
0.17 USD
Aug. 20, 2025 0.1730
▸2021
0.46 USD
June 14, 2021 0.4560
▸2020
0.20 USD
Nov. 9, 2020 0.2010
▸2019
0.39 USD
Dec. 11, 2019 0.2200
June 18, 2019 0.1740
▸2018
0.48 USD
Dec. 11, 2018 0.2280
June 12, 2018 0.2510
▸2017
0.38 USD
Dec. 12, 2017 0.2120
June 8, 2017 0.1630
▸2016
0.35 USD
Dec. 14, 2016 0.1910
June 15, 2016 0.1590
▸2015
0.35 USD
Dec. 17, 2015 0.1850
June 15, 2015 0.1675
▸2014
0.30 USD
Dec. 12, 2014 0.1565
June 13, 2014 0.1435
▸2013
0.14 USD
June 13, 2013 0.1295
May 29, 2013 0.0065
Upcoming Dividends
Name Payment Date Status Amount
Grifols, S.A. Dec 11, 2026 Upcoming 0.13655 USD
Grifols, S.A. Jul 09, 2026 0.094458 USD
Stock Splits
Split Date Split Ratio to 1
July 23, 2012 1:2
Dec. 11, 2012 1.05
Jan. 4, 2016 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion